IRAK4 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the human T-cell leukemia line Jurkat E6.1, with functional disruption of the IRAK4 gene. This heterogeneous pool enables loss-of-function studies without clonal selection, providing a reproducible model for investigating innate immune signaling pathways.
Jurkat E6.1 is a widely used suspension lymphoblast line originating from an acute T-cell leukemia patient. It retains key T-cell signaling machinery and is extensively employed to study T-cell activation, cytokine regulation, and apoptosis, making it a relevant host for examining IRAK4-dependent pathways in a lymphocytic context.
IRAK4 encodes a serine/threonine kinase that acts as a pivotal signal transducer downstream of Toll-like receptors (TLRs) and the interleukin-1 receptor (IL-1R). Upon ligand stimulation??such as LPS or IL-1?¡?IRAK4 is recruited to the receptor via the adaptor MyD88, where it forms the Myddosome complex with IRAK1, IRAK2, and Pellino proteins. IRAK4 autophosphorylation triggers phosphorylation of IRAK1, initiating a cascade through TRAF6 and TAK1 that activates the IKK complex. This leads to I??B?? degradation and NF-??B nuclear translocation, along with JNK and p38 MAP kinase activation, driving transcription of pro-inflammatory cytokines.
In Jurkat cells, IRAK4 ablation disrupts MyD88-dependent signaling, blocking NF-??B and MAPK responses to TLR and IL-1R agonists. Given that Jurkat cells express these receptors, the knockout allows dissection of innate immune cross-talk with T-cell receptor pathways. The model is valuable for verifying drug targets, as loss of IRAK4 phenocopies pharmacological inhibition, and can be used to validate the specificity of IRAK4 inhibitors. Additionally, it aids in exploring immunodeficiency-related signaling defects and evaluating anti-inflammatory strategies.
Researchers can employ these cells in Western blotting for IRAK4 and phospho-IRAK1, RT-qPCR of cytokine transcripts, NF-??B reporter assays, ELISA for secreted cytokines, and phospho-flow cytometry for p65 and JNK activation. The polyclonal format preserves genetic variability, offering robust population-level data and reducing clonal artifacts. For further details, please contact Ascent Research.
